Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (3150)	12/5/1997 7:47:00 AM
From: sam	Read Replies (1) \| Respond to of 6136

On the PW conference call, it was clear that AGPH expected excellent European sales of Viracept (as I reported in my previous post, Roche is ramping up for a major run). Other points made by Johnson, there has been no scientific brain drain at AGPH. And, he stated his belief that it is absurd to see Viracept as a flash in the pan. It'll be around, he said, "for decades." As for sales to Africa/Asia, all the estimates for AGPH earnings assume no sales to areas that cannot afford the drug.